CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to NVS

Aliskiren 3.125 mini-tablets

Phase 2
Novartis AG (NVS)

Phase 2

Development Phase

0

Upcoming Catalysts

0

Historical Events

5

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

Hypertension

Clinical Trial

NCT00834041

Last updated: 1/10/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals
EMA8/22/2007

Sprimeo

Treatment of essential hypertension.

View on EMA
EMA8/22/2007

Riprazo

Treatment of essential hypertension.

View on EMA
EMA8/22/2007

Enviage

Treatment of essential hypertension

View on EMA
EMA8/22/2007

Tekturna

Treatment of essential hypertension

View on EMA
EMA8/22/2007

Rasilez

Treatment of essential hypertension.

View on EMA
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.